The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

Eli Lilly (LLY) announced the FDA approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe obstructive ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The FDA has approved Eli Lillys Zepbound as the first weight-loss drug to treat obstructive sleep apnea, reshaping care for ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The U.S. Food and Drug Administration has approved Eli Lilly and Co. ’s obesity-treatment Zepbound as the first medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. Lilly ...

Now, new research suggests Eli Lilly’s weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality. Since sleep ...